Area of research
Cancer Research · Biotechnology
Research interest
Research interests include Cancer, Hypoxia, and Metabolism, Cancer Research and Treatments, ATP Synthase and ATPases Research, and Mechanisms of cancer metastasis.
Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
An innovative virtual fellowship leveraging global and regional mentorship to foster pediatric neuro-oncologists in low/middle-income countries
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
A manifesto on improving cancer care in conflict-impacted populations
652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia